File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/cam4.4888
- Scopus: eid_2-s2.0-85131016004
- PMID: 35642123
Supplementary
- Citations:
- Appears in Collections:
Article: Clinical characteristics, risk factors and outcomes of cancer patients with COVID-19: A population-based study
Title | Clinical characteristics, risk factors and outcomes of cancer patients with COVID-19: A population-based study |
---|---|
Authors | |
Keywords | cancer COVID-19 intensive care unit intubation mortality |
Issue Date | 2023 |
Citation | Cancer Medicine, 2023, v. 12, n. 1, p. 287-296 How to Cite? |
Abstract | Introduction: Cancer patients may be susceptible to poorer outcomes in COVID-19 infection owing to the immunosuppressant effect of chemotherapy/radiotherapy and cancer growth, along with the potential for nosocomial transmission due to frequent hospital admissions. Methods: This was a population-based retrospective cohort study of COVID-19 patients who presented to Hong Kong public hospitals between 1 January 2020 and 8 December 2020. The primary outcome was a composite endpoint of requirement for intubation, ICU admission and 30-day mortality. Results: The following study consisted of 6089 COVID-19 patients (median age 45.9 [27.8.1–62.7] years; 50% male), of which 142 were cancer subjects. COVID-19 cancer patients were older at baseline and tended to present with a higher frequency of comorbidities, including diabetes mellitus, hypertension, chronic obstructive pulmonary disease, ischemic heart disease, ventricular tachycardia/fibrillation and gastrointestinal bleeding (p < 0.05). These subjects also likewise tended to present with higher serum levels of inflammatory markers, including D-dimer, lactate dehydrogenase, high sensitivity troponin-I and C-reactive protein. Multivariate Cox regression showed that any type of cancer presented with an almost four-fold increased risk of the primary outcome (HR: 3.77; 95% CI: 1.63–8.72; p < 0.002) after adjusting for significant demographics, Charlson comorbidity index, number of comorbidities, past comorbidities and medication history. This association remained significant when assessing those with colorectal (HR: 5.07; 95% CI: 1.50–17.17; p < 0.009) and gastrointestinal malignancies (HR: 3.79; 95% CI: 1.12–12.88; p < 0.03), but not with lung, genitourinary, or breast malignancies, relative to their respective cancer-free COVID-19 counterparts. Conclusions: COVID-19 cancer patients are associated with a significantly higher risk of intubation, ICU admission and/or mortality. |
Persistent Identifier | http://hdl.handle.net/10722/330806 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhou, Jiandong | - |
dc.contributor.author | Lakhani, Ishan | - |
dc.contributor.author | Chou, Oscar | - |
dc.contributor.author | Leung, Keith Sai Kit | - |
dc.contributor.author | Lee, Teddy Tai Loy | - |
dc.contributor.author | Wong, Michelle Vangi | - |
dc.contributor.author | Li, Zhen | - |
dc.contributor.author | Wai, Abraham Ka Chung | - |
dc.contributor.author | Chang, Carlin | - |
dc.contributor.author | Wong, Ian Chi Kei | - |
dc.contributor.author | Zhang, Qingpeng | - |
dc.contributor.author | Tse, Gary | - |
dc.contributor.author | Cheung, Bernard Man Yung | - |
dc.date.accessioned | 2023-09-05T12:14:36Z | - |
dc.date.available | 2023-09-05T12:14:36Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Cancer Medicine, 2023, v. 12, n. 1, p. 287-296 | - |
dc.identifier.uri | http://hdl.handle.net/10722/330806 | - |
dc.description.abstract | Introduction: Cancer patients may be susceptible to poorer outcomes in COVID-19 infection owing to the immunosuppressant effect of chemotherapy/radiotherapy and cancer growth, along with the potential for nosocomial transmission due to frequent hospital admissions. Methods: This was a population-based retrospective cohort study of COVID-19 patients who presented to Hong Kong public hospitals between 1 January 2020 and 8 December 2020. The primary outcome was a composite endpoint of requirement for intubation, ICU admission and 30-day mortality. Results: The following study consisted of 6089 COVID-19 patients (median age 45.9 [27.8.1–62.7] years; 50% male), of which 142 were cancer subjects. COVID-19 cancer patients were older at baseline and tended to present with a higher frequency of comorbidities, including diabetes mellitus, hypertension, chronic obstructive pulmonary disease, ischemic heart disease, ventricular tachycardia/fibrillation and gastrointestinal bleeding (p < 0.05). These subjects also likewise tended to present with higher serum levels of inflammatory markers, including D-dimer, lactate dehydrogenase, high sensitivity troponin-I and C-reactive protein. Multivariate Cox regression showed that any type of cancer presented with an almost four-fold increased risk of the primary outcome (HR: 3.77; 95% CI: 1.63–8.72; p < 0.002) after adjusting for significant demographics, Charlson comorbidity index, number of comorbidities, past comorbidities and medication history. This association remained significant when assessing those with colorectal (HR: 5.07; 95% CI: 1.50–17.17; p < 0.009) and gastrointestinal malignancies (HR: 3.79; 95% CI: 1.12–12.88; p < 0.03), but not with lung, genitourinary, or breast malignancies, relative to their respective cancer-free COVID-19 counterparts. Conclusions: COVID-19 cancer patients are associated with a significantly higher risk of intubation, ICU admission and/or mortality. | - |
dc.language | eng | - |
dc.relation.ispartof | Cancer Medicine | - |
dc.subject | cancer | - |
dc.subject | COVID-19 | - |
dc.subject | intensive care unit | - |
dc.subject | intubation | - |
dc.subject | mortality | - |
dc.title | Clinical characteristics, risk factors and outcomes of cancer patients with COVID-19: A population-based study | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1002/cam4.4888 | - |
dc.identifier.pmid | 35642123 | - |
dc.identifier.scopus | eid_2-s2.0-85131016004 | - |
dc.identifier.volume | 12 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 287 | - |
dc.identifier.epage | 296 | - |
dc.identifier.eissn | 2045-7634 | - |